Cancer-Related CD15/FUT4 Overexpression Decreases Benefit to Agents Targeting EGFR or VEGF Acting as a Novel RAF-MEK-ERK Kinase Downstream Regulator in Metastatic Colorectal Cancer

Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/s13046-015-0225-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting the Ras/Raf/Mek/Erk Pathway in Hepatocellular Carcinoma (Review)

Oncology Letters
Cancer ResearchOncology
2017English

Simultaneous Targeting of RAF, MEK, and ERK Limits Drug Resistance

Cancer Discovery
Oncology
2017English

Future of Targeted Agents in Metastatic Colorectal Cancer

Colorectal Cancer
OncologyGastroenterology
2012English

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Tumour-Infiltrating Neutrophils Counteract Anti-Vegf Therapy in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Targeting Alterations in the RAF–MEK Pathway

Cancer Discovery
Oncology
2019English

Control of Drosophila Photoreceptor Cell Fates by Phyllopod, a Novel Nuclear Protein Acting Downstream of the Raf Kinase

Cell
BiochemistryGeneticsMolecular Biology
1995English

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

New Therapeutic Agents for Metastatic Colorectal Cancer: Literature Review

Colorectal Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy